Navigation Links
Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT)
Date:7/10/2014

t patients or discharge them on outpatient therapy.
  • Preference for oral antibiotics over OPAT: Oral therapies offer the potential to substantially simplify antibiotic treatment compared with therapies that are administered intravenously. Not surprisingly, surveyed ID specialists reported being more likely to prescribe oral formulations of both Cubist's Sivextro (tedizolid) and Tetraphase's emerging drug eravacycline when discharging patients than OPAT with either drug, suggesting oral formulations of these agents will see greater use as discharge therapy.
  • Comments from Decision Resources Group Analyst Hannah E. Cummings, Ph.D.:

    • "Hospitals are actively looking to cut costs and reduce or shorten admissions, and discharging patients on OPAT is an important part of their strategy. OPAT is a particularly attractive treatment modality for patients presenting to the emergency room with an infection requiring IV antibiotic therapy but not necessitating admission. ID specialists and emergency room physicians are frequently involved in identifying and recommending patients for OPAT and will likely be key stakeholders in driving uptake of new OPAT therapies."
    • "Surveyed ID specialists identified a need for new OPAT drugs for infections due to drug-resistant pathogens that are dosed once daily. Although the OPAT market is highly genericized, agents demonstrating benefits in efficacy, dosing-frequency and/or administration, such as Cubist's Cubicin (daptomycin) and Merck's Invanz (ertapenem), have experienced widespread use in the OPAT market. New agents will also have to demonstrate improvements on these key attributes to successfully compete in the OPAT market segment."

    About Decision Resources Group
    Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare indu
    '/>"/>

    SOURCE Decision Resources Group
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Janssen R&D Ireland Announces Agreement with PATH for Early Development of Rilpivirine in Long-Acting Formulation for Potential Prophylactic Intervention
    2. Beyond the Headlines: What the FDA Decisions on Extended-release and Long-Acting Opioids Mean for People With Pain
    3. WomanCare Global launches Simplant, Long-acting Reversible Contraception, in Chile
    4. PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
    5. Study Published In Contraception Evaluates Medical Expenditures For Unintended Pregnancies And Potential Cost Impact Of Increased Use Of Long-Acting Reversible Contraception
    6. Purdue Pharma L.P. Comments on FDA Announcement on REMS for Extended-Release and Long-Acting Opioid Analgesics
    7. Applegate CEO Worries FDA Plan To Address Antibiotics In Animal Agriculture Is Too Little, Too Late
    8. AVMA lauds FDA for new regulation of antibiotics in livestock feed
    9. Debiopharm Group and TCG Lifesciences Ltd. Enter into an Exclusive Research Agreement to Develop a Novel Class of Antibiotics, a New Strategic Therapeutic Area for Debiopharm
    10. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
    11. Antibiotic Resistance 2013: The Antibiotics Development Pipeline and Strategies to Combat Antibiotic Resistance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2015)... , Sept. 1, 2015  AccuTec Blades, Inc. today ... Industrial Blades division.  EPC announced in May 2015 its ... Verona, Virginia and Obregon, ... the sale process. Rick Gagliano ... AccuTec Blades said, "Our new name, AccuTec Blades, reflects ...
    (Date:9/1/2015)... , Sept. 1, 2015 Nevro Corp. ... that is providing innovative evidence-based solutions for the treatment ... submitted its preliminary response to the Patent Trial and ... inter partes review (IPR), filed by a unit ... claims in U.S. Patent No. 8,359,102 (the ,102 patent). The ...
    (Date:9/1/2015)... YEHUDA, Israel , Sept. 1, 2015 ... ), a leading innovator of less invasive, miniaturized circulatory ... heart failure, announced today that it has entered into ... . ("Valtech").  Valtech is a privately held company that ... valve repair and replacement devices for the treatment of ...
    Breaking Medicine Technology:AccuTec Blades, Inc. Announces Acquisition of Industrial Blades Division from Edgewell Personal Care Company 2Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 3HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 4HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 5HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 6HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 7HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 8HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 9HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 10
    ... March 30, 2011 Regado Biosciences, a privately held ... control agents, announced that David J. Mazzo, PhD, President ... Company,s 10th Annual Healthcare Conference at the New York ... 6, 2011 at 11:20 a.m. EDT.  The presentation will ...
    ... Inc. (Nasdaq: ABAX ), a medical products company ... chairman and chief executive officer,  will present at the 10th ... 8:40 a.m. ET. The conference will be held at the ... About Abaxis Abaxis develops, manufactures and markets portable blood ...
    Cached Medicine Technology:Regado Biosciences to Present at the Needham & Company's 10th Annual Healthcare Conference in New York City 2Regado Biosciences to Present at the Needham & Company's 10th Annual Healthcare Conference in New York City 3
    (Date:9/1/2015)... ... ... From Aug. 17-21, Calvary Hospital hosted the 18th consecutive session of its bereavement ... place at Kingsborough Community College in Brooklyn in each of the past three years. ... two junior counselors who were campers themselves just a few years ago. , The ...
    (Date:9/1/2015)... ... September 01, 2015 , ... Horizon Blue Cross Blue Shield of New Jersey ... in the LATINA Style 50 Report that recognizes companies that provide the best career ... Horizon BCBSNJ climbs from number 24 to 21 of the 50 Best Companies for ...
    (Date:9/1/2015)... ... September 01, 2015 , ... ... prevent different malignancies. Some options for cancer treatment are available belonging to ... distinctive approach is necessary for effective treatment. Several molecules have been discovered ...
    (Date:9/1/2015)... , ... September 01, 2015 , ... ... delivery options, Blue Cross and Blue Shield of Minnesota (Blue Cross) has announced ... , Based in San Francisco, Doctor On Demand provides immediate access to ...
    (Date:9/1/2015)... ... September 01, 2015 , ... ... creates negative pressure inside a wound to remove exudates, fluid, and infectious materials ... (comprising portable devices, stand-alone devices, disposable devices, and canisters, etc.) is projected to ...
    Breaking Medicine News(10 mins):Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3
    ... new study it was found that researchers at the UC ... amino acids // . The speciality of this discovery is ... and specificity towards leukemic and lymphoma cells. Hence researchers say ... deliver anti-cancer drugs. ,The study results were published ...
    ... nonepileptic seizures, or psychogenic seizures are often misdiagnosed as ... //whereas epilepsy is caused by the abnormal electrical activity ... seizures are similar to epileptic seizures, they can be ... June 13, 2006, issue of Neurology, the scientific journal ...
    ... that a short course of a drug could relieve severe ... million youngsters in mainly poor countries each year. ... Romark Laboratories under the brand name Alinia, had been found ... in young children with a severe form of the illness. ...
    ... to completely avoid consuming Vitamin E supplements, as this is ... ,A leading obstetrician, Prof Stuart Campbell, has appealed to ... following clinical trials that have revealed that this vitamin can ... known to increase the rates of still births and cause ...
    ... news agency reports, northern Ukraine faces the initial attack of ... destroy domestic poultry //. ,In southern Ukraine, ... peninsula, firstly diagnosed a case of avian flu in last ... to villagers and done so by the Ukraine's Emergencies Ministry, ...
    ... scientists have claimed that they have identified three new cataract-causing ... in families in India. ,Scientists from the Center ... with researchers from the National Institute of Health, USA and ... 30 years of research in the field of ophthalmology, to ...
    Cached Medicine News:Health News:New Molecular Treatment Identified To Treat Blood Cell Cancers 2Health News:Clues To Identify Psychological Seizures 2Health News:Clues To Identify Psychological Seizures 3Health News:Indian Scientists Identify Cataract Causing Genes 2
    The NexGen CR femoral component is intended for patients who, in the physician's judgement, have good bone stock and whose ligaments provide adequate mediolateral, anteroposterior, and varus/valgus s...
    Cruciate retaining, posterior stabilized and constrained components....
    The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
    ...
    Medicine Products: